top of page
grey-9026_256.gif

$21.5 Million Revenue, Military-Focused Orthotics, Bracing, & DME Platform Seeking Majority Recapitalization

Listing Code:

XYDME2G

UNDER LOI

State:

Not Disclosed

Category:

Orthotics & Prosthetics

Asking Price:

$50,000,000

Revenue:

$21,500,000

XYDME2G

Company Overview

PRIME exits® and American HealthCare Capital are proud to exclusively represent a rare opportunity to invest in a highly specialized healthcare products and services company providing custom orthotics, orthopedic bracing, electrotherapy, and durable medical equipment to a difficult-to-reach federal and military healthcare population. The Company has built a strong market position through years of provider education, military site access procedures, patient service, trained and credentialed staff, and select product relationships.

The Company’s business model is not built around general civilian retail DME. Instead, it has established a repeatable referral and fitting model within a federal healthcare ecosystem serving active-duty personnel, veterans, and their families. This creates an economic moat rooted in specialized access, provider trust, operational know-how, and mission-specific brand positioning.

Investment Highlights 2025A revenue of approximately $17.9M and 2025A adjusted EBITDA / operating income of approximately $4.1M.2026E base case of approximately $21.5M revenue and $5.2M adjusted EBITDA.Custom orthotics and orthopedic products represent the core revenue driver.Dedicated federal / military healthcare niche with meaningful barriers to entry.Multi-state footprint with international service capability.Growth opportunities in new territories, government contracts, commercial payers, retail / e-commerce, and product expansion.

Competitive Advantages Access to a specialized federal healthcare patient population.Provider education and ordering workflow expertise.Trained and credentialed patient-facing workforce.Select product relationships and military-specific product positioning.Mission-first brand with strong patient service reputation.Existing infrastructure expected to support growth with operating leverage.

Metric

2022A

2023A

2024A

2025A

2026E Base Case

Revenue

$15.1M

$18.0M

$16.4M

$17.9M

$21.5M

Adjusted EBITDA / Operating Income

$3.5M

$4.9M

$4.1M

$4.1M

$5.2M

Margin

22.9%

27.1%

24.7%

23.2%

24.2%

YoY Revenue nd Growth

—

19.1%

(8.8%)

8.7%

20.3%

YoY Adj. EBITDA Growth

—

40.9%

(16.9%)

2.2%

25.5%

Transaction Overview & Valuation

The Company is seeking an equity partnership to accelerate its next phase of growth. The management team is open to a variety of transaction structures, including a majority sale, rollover equity, earn-outs, and other customized arrangements. The asking price is $50,000,000 on a cash-free, debt-free basis. The purchase price excludes cash, accounts receivable, working capital, excess inventory, and all real estate holdings and properties

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.

YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE. 

2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:

XYDME2G

Listing Title:

$21.5 Million Revenue, Military-Focused Orthotics, Bracing, & DME Platform Seeking Majority Recapitalization

Heading 4

Need to learn more before Signing an NDA- Contact the Lead Advisor For This Mandate

Dr. Allen

Listing Title:

Error
Error

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi

President/Founder

American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

Join our mailing list to receive our latest news, and listings

About PRIME exits®
​

​​

​

Locations
Copyrights Reserved 2026 @ PRIME exits®
bottom of page